Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare-disease drugmaker, is closing in on a financial turning point, according to research house Edison.
In a QuickView note published on Tuesday, analysts Jyoti Prakash and Arron Aatkar said the company was on track to reach cash flow break-even in the third quarter, completing its shift into a self-funded business.
Edison does not attach a formal rating or price target to its QuickView notes, which lean on consensus estimates.
The investment case rests on AGAMREE, known generically as vamorolone, the first dissociative corticosteroid approved for Duchenne muscular dystrophy (DMD), a rare and progressive muscle-wasting condition.
The drug has captured about 40% of corticosteroid-treated DMD patients in Germany and roughly 50% in Austria, with UK adoption tracking Germany’s early trajectory.
Unlike conventional steroids, AGAMREE is designed to preserve anti-inflammatory efficacy while limiting the side effects of long-term use.
Edison pointed to data showing about 80% fewer vertebral fractures than deflazacort, a widely used alternative, as evidence of its differentiated profile.
Planned launches in Spain and Italy during the second half of 2026 should provide the next growth catalyst.
The analysts also flagged Santhera’s hybrid commercial model, which pairs direct selling across Europe with regional licensing deals.
Those partnerships include Catalyst in North America, Sperogenix in China and Nxera in Japan and the wider Asia-Pacific region.
The approach lets Santhera keep the full economics of its core European markets while collecting milestone and royalty income elsewhere.
A $40 million upfront payment from the January 2026 Nxera agreement underpins the path to break-even without further financing.
Management is guiding to revenue of CHF80 million to CHF90 million for the 2026 financial year, and has set a €150 million revenue ambition for 2028.
The forecasts follow a strong 2025, when revenue rose 97% to CHF77.2 million, comfortably ahead of guidance, though the company still posted a pre-tax loss of CHF49.1 million.
Edison named the key risks as reliance on a single product, dependence on partners for international growth, and continued exposure to reimbursement decisions.
The shares stood at CHF15.90, valuing the group at CHF252 million.
Source link
